Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.61 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2671896 | 1.00 | FOLH1 (0.61) | FOLH1CAMK2ALMNASLC22A6TSHR | |
| SCHEMBL25412244 | 1.00 | FOLH1 (0.61) | FOLH1CAMK2ALMNASLC22A6TSHR | |
| SCHEMBL28038839 | 1.00 | FOLH1 (0.61) | FOLH1CAMK2ALMNASLC22A6TSHR | |
| SCHEMBL27960589 | 0.93 | FOLH1 (0.73) | FOLH1CAMK2ALMNASLC22A6TSHR | |
| SCHEMBL2672065 | 0.93 | FOLH1 (0.73) | FOLH1CAMK2ALMNASLC22A6TSHR | |
| SCHEMBL11775872 | 0.91 | FOLH1 (0.70) | FOLH1LMNASLC22A6TSHRNFKB1 | |
| SCHEMBL4365206 | 0.91 | FOLH1 (0.70) | FOLH1LMNASLC22A6TSHRNFKB1 | |
| SCHEMBL2671889 | 0.91 | FOLH1 (0.70) | FOLH1LMNASLC22A6TSHRNFKB1 | |
| SCHEMBL27960577 | 0.91 | FOLH1 (0.70) | FOLH1LMNASLC22A6TSHRNFKB1 | |
| SCHEMBL1852983 | 0.87 | FOLH1 (0.52) | FOLH1CAMK2ASLC22A6TSHRGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692055-A1 | THIOL COMPOUND | AJINOMOTO CO., INC. (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008904-A1 | THIOL COMPOUND | AJINOMOTO CO., INC. (JP) | 2026-01-08 | — | — | US | disclosed |
| WO-2024204053-A1 | THIOL COMPOUND | 味の素株式会社 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024204052-A1 | THIOL COMPOUND | 味の素株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-20230287250-A1 | THERMOSETTING COMPOSITON, CURED PRODUCT, DEVICE, AND METHOD FOR MANUFACTURING THE DEVICE | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-8283095-B2 | Thiourethane compound and photosensitive resin composition | SHOWA DENKO K.K. (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20100233596-A1 | THIOURETHANE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | SHOWA DENKO K.K. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2055726-A1 | THIOURETHANE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Showa Denko K.K. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233596-A1 | THIOURETHANE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | RCOR3, CBR3, TAS2R3 | FOLH1 2485/4885CAMK2A 4182/4885LMNA 4454/4885 |
| US-20260008904-A1 | THIOL COMPOUND | CBR1, PSMA1, KAT2A | FOLH1 3781/4885CAMK2A 4469/4885LMNA 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.